Developer docs
API playgroundTry for free, no card

Search company profiles

AlveoliX AG

Full company profile

uuid0008qyd

Namestring
AlveoliX AG
Legal namestring
AlveoliX AG
Websiteurl
alveolix.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

AlveoliX AG is a Swiss biotech tools company founded in 2019 as a spin-off from the University of Bern's ARTORG Center for Biomedical Engineering Research, specializing in organ-on-chip and barrier-on-chip in vitro systems for pharmaceutical drug discovery and preclinical testing. The company's core product platforms are the AXLung-on-Chip System and the AXBarrier-on-Chip System, built around a proprietary AX12 microfluidic chip with an ultrathin 3.5µm elastic membrane and connected via the AXDock to the AXExchanger (fluid control with TEER measurement) and the AXBreather (pneumatic controller that simulates 12 cycles/min breathing motion with 8% linear strain). On top of this hardware, AlveoliX sells AXBiomodels (pre-developed monoculture, co-culture, immune, inflammation, and fibrosis models) and, since June 2023, AX Cells-on-Chip pre-seeded consumables. Its core technology is protected by a granted US patent on the breathing-motion lung-on-chip design and benefits from the regulatory tailwind of the FDA Modernization Act 2.0, which enables organ-on-chip data as standalone preclinical evidence.

The company operates a direct B2B sales model targeting pharmaceutical and biotech companies, contract research organizations, and academic research institutions, supported by participation in major scientific conferences (SOT, EUROTOX, ERS, EUROoCS) and a partnership-driven approach for technology validation and disease-specific applications. Named enterprise customers include Roche (Biochip Storming AX collaboration) and CSL Behring (sitem-insel hub partnership for lung disease translation), with academic collaborators including the Francis Crick Institute for iPSC-derived lung infection models and the University of Bern / Inselspital as founding academic partners. Revenue is generated through hardware sales of the chip ecosystem, consumables (chips, AX Cells-on-Chip), and professional services for custom biomodel development and research collaborations.

AlveoliX is headquartered in Bern, Switzerland (Freiburgstrasse 3, near sitem-insel) with a production site in Biel/Bienne at the Switzerland Innovation Park, and serves primarily European customers with selective North American outreach. Funding has come almost entirely from non-dilutive grants (Eurostars, Innosuisse, SNSF BRIDGE Discovery) rather than priced venture capital, and the company is led by co-CEOs Dr. Nina Hobi and Dr. Janick Stucki, with Prof. Olivier Guenat, the technology originator, remaining on the Board. In 2026, AlveoliX co-founded IAMPS, the first European industry association for microphysiological systems providers, alongside eight peer companies, positioning the firm as a standards-setter in the emerging organ-on-chip category.

Short descriptiontext

AlveoliX AG is a Swiss biotech tools company that develops proprietary organ-on-chip and lung-on-chip in vitro systems with breathing-motion simulation, selling hardware, consumables, and disease-specific biomodels to pharmaceutical, biotech, CRO, and academic customers for preclinical drug testing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBern, Switzerland
HQ citystring
Bern
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
organ-on-chip technology, lung-on-chip systems, in vitro preclinical models, microphysiological systems, barrier-on-chip platform
Industry5 codes
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHLAGAIAG
Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers)
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Laboratory Analytical Instruments3826
Product category
Organ-on-Chip / Microphysiological Systems
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Organ-on-Chip Systems and Products
TypeHardware Sales
Description

Sale of AX12 chips, AXLung-on-Chip System, AXBarrier-on-Chip System and related consumables for drug discovery and preclinical research.

alveolix.com
2AXBiomodels and Custom Model Development
TypeProfessional Services
Description

Provision of disease-specific biomodels and custom model development services for pharmaceutical and biotech company research needs.

alveolix.com
3Research Collaborations
TypeProfessional Services
Description

Collaborative research projects with academic institutions and pharmaceutical partners for specific disease applications.

genengnews.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

AlveoliX AG designs, manufactures, and sells proprietary organ-on-chip platforms — primarily the AXLung-on-Chip and AXBarrier-on-Chip Systems — that recreate human lung and barrier microenvironments in vitro with mechanical breathing simulation. The company supplies the AX12 chip, AXDock, AXExchanger, and AXBreather hardware, together with AXBiomodels (pre-developed toxicity, inflammation, and fibrosis models) and the AX Cells-on-Chip line of pre-seeded chips, for pharmaceutical and biotech drug discovery and preclinical testing applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 87% sensitivity in predicting drug-induced liver injury (FDA ISTAND pilot program for comparable MPS technologies)
Product overview1 text field

AlveoliX AG offers a modular organ-on-chip product ecosystem centered on two core platforms: the AXLung-on-Chip System and the AXBarrier-on-Chip System. The AXLung-on-Chip System includes the AX12 chip (96-well format with 6 independent units), AXDock, AXExchanger, and AXBreather components that work together to recreate breathing lung models with ultrathin membranes (3.5µm) and cyclic strain (12 cycles/min, 8% linear strain). The AXBarrier-on-Chip System provides barrier modeling capability. Both platforms use the AXBiomodels library (monoculture, co-culture, immuno, inflammation, fibrosis models) for specific testing applications. The AX Cells-on-Chip line extends the portfolio with pre-seeded cells for standardized workflows. The systems are designed for drug discovery, preclinical toxicity and efficacy testing, and are compatible with standard laboratory equipment and readouts including TEER, ELISA, rtPCR, and flow cytometry.

Product and service4 records
1AXLung-on-Chip System
CategoryCore Product
Description

A lung-on-chip system that replicates the human lung microenvironment with breathing motion, including the AX12 chip (ultrathin 3.5µm membrane with 3µm pores), AXDock connection hub, AXExchanger for fluid control, and AXBreather for pneumatic breathing simulation (12 cycles/min, 8% linear strain). Designed for pharmaceutical and biotech drug discovery and preclinical studies.

2AXBarrier-on-Chip System
CategoryCore Product
Description

A barrier-on-chip platform that recreates the air-blood barrier with human-derived cells for in vitro toxicity and efficacy testing in drug discovery and preclinical studies, supporting mono-culture, co-culture, and immune cell integration.

3AX Cells-on-Chip
CategoryCore Product
Description

Product line of cells pre-seeded on the AX chip platform, providing standardized, ready-to-use in vitro testing models for drug testing applications.

4AXBiomodels
CategoryResearch and Service
Description

Disease-specific in vitro biomodels including toxicity models (monoculture, co-culture, immuno), efficacy models (inflammation, fibrosis), and custom model development services for pharmaceutical and biotech company research needs.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
1European WiFIX Consortium Partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-09
Description

European consortium awarded EUR 1 million Eurostars grant to develop Nexopore, a wireless electroporation-based system for delivering nucleic acid therapeutics. AlveoliX is part of this consortium focused on overcoming delivery challenges for nucleic acid therapeutics.

startupticker.ch
Strategic tierCoreTypeTechnology or Integration
Description

Co-developed new immortalized alveolar cell line (AXiAECs) combining InSCREENeX's CI-SCREEN methodology with AlveoliX's organ-on-chip technology. Cells derived from primary alveolar epithelial cells feature tight barrier formation and robust marker expression.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

EPIColiX project under Eurostars program developing gut-on-chip model for drug testing. AlveoliX developing colon epithelium model for screening EpiEndo's lead compounds for ulcerative colitis treatment.

4PANC-CKI Consortium
Strategic tierMajorTypeStrategic or Co-development Partner
Description

AlveoliX part of consortium led by CasInvent Pharma awarded €4M Eurostars grant for pancreatic cancer research. Consortium achieved top ranking in Czech Republic, Switzerland, and overall.

alveolix.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Hosted first Biochip Storming AX event with Roche Basel to address challenges and opportunities of organ-on-chip technology within drug development pipeline.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CSL Behring, Insel Gruppe and AlveoliX joined forces within sitem-insel AG's hub to improve translation and find new treatments for lung diseases.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint development of first human lung-on-chip model using stem cells from a single donor, capable of simulating breathing motions and replicating lung disease for personalized medicine applications. Tested with tuberculosis infection.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-term academic partnership for organ-on-chip technology development. Founding relationship where technology originated from Prof. Olivier Guenat's research group.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Switzerland's largest hospital group, partner in lung research and clinical translation of organ-on-chip technology for patient benefit.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founded with 8 other European MPS companies (BiomimX, Chiron, Dynamic42, InSphero, MIMETAS, NETRI, React4Life, TissUse) as the world's first industry association dedicated to representing microphysiological systems providers. Association aims to increase regulatory acceptance, create data-sharing platforms, and advance device standardization.

11BRIDGE Discovery Project Consortium
Strategic tierMajorTypeStrategic or Co-development Partner
Description

SNSF/Innosuisse funded project with Université de Neuchâtel, CHUV, SIB, and SiMPLInext SA to establish novel solution for antibiotic resistance using environmental interference to fight lung fungal infections.

alveolix.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Part of MPS initiative working to increase industry adoption and regulatory acceptance of MPS technologies with the goal of refining, reducing, and replacing research animals.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based organ-on-chip company commercializing the Emulate Liver-Chip and other organ models for pharma R&D. Direct competitor to AlveoliX's AXLung/AXBarrier-on-Chip platforms with overlapping target customers in big pharma and similar microfluidic chip-plus-instrument business model.

TypeDirect peer
Description

German organ-on-chip company developing immune-system and infection-on-chip models for pharma and academic research. Direct competitor, fellow IAMPS co-founder, and comparable European early-commercial MPS provider.

3CN Bio Innovations
TypeDirect peer
Description

UK-based organ-on-chip company commercializing the PhysioMimix platform for liver and lung MPS models. Direct competitor with comparable single- and multi-organ chip offerings aimed at pharma toxicology and disease modeling.

TypeDirect peer
Description

French organ-on-chip company industrializing microfluidic neural and organ-on-chip devices for pharma screening. Direct competitor in MPS hardware, fellow IAMPS co-founder, with overlapping target use cases in neurological and systemic drug testing.

TypeRegional player
Description

French organ-on-chip company offering the Chipster platform with temperature-controlled microfluidic MPS systems for academic and pharma research. Comparable European MPS provider serving overlapping applications in cell-based preclinical testing.

TypeDirect peer
Description

Italian organ-on-chip startup focused on heart and vascular MPS models using beating-cardiac technology. Direct competitor and fellow IAMPS co-founder with similar early-stage European MPS positioning.

TypeDirect peer
Description

Dutch organ-on-chip company offering the OrganoPlate platform for high-throughput 3D tissue models. Direct competitor targeting pharmaceutical drug discovery and toxicology with comparable organ-on-chip hardware, consumables, and custom model services.

TypeDirect peer
Description

Italian organ-on-chip company commercializing the MIVO (Multi-In-Vitro-Organ) platform for fluid-dynamic tissue models. Direct competitor in MPS-based preclinical testing, fellow IAMPS co-founder, with comparable European pharma and academic customer base.

TypeDirect peer
Description

German multi-organ-on-chip company offering the HUMIMIC chip systems for substance testing. Direct competitor in MPS hardware with overlapping pharma customer base and fellow IAMPS co-founder.

TypeDirect peer
Description

Swiss 3D cell culture and organ-on-chip company providing liver, islet, and tumor microtissues for drug safety/efficacy testing. Direct competitor in MPS-based preclinical tools, fellow IAMPS co-founder, and similarly Swiss-based with overlapping pharma customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AlveoliX AG

Organ-on-Chip / Microphysiological Systemsalveolix.com

AlveoliX AG is a Swiss biotech tools company that develops proprietary organ-on-chip and lung-on-chip in vitro systems with breathing-motion simulation, selling hardware, consumables, and disease-specific biomodels to pharmaceutical, biotech, CRO, and academic customers for preclinical drug testing.

What AlveoliX AG does

AlveoliX AG is a Swiss biotech tools company founded in 2019 as a spin-off from the University of Bern's ARTORG Center for Biomedical Engineering Research, specializing in organ-on-chip and barrier-on-chip in vitro systems for pharmaceutical drug discovery and preclinical testing. The company's core product platforms are the AXLung-on-Chip System and the AXBarrier-on-Chip System, built around a proprietary AX12 microfluidic chip with an ultrathin 3.5µm elastic membrane and connected via the AXDock to the AXExchanger (fluid control with TEER measurement) and the AXBreather (pneumatic controller that simulates 12 cycles/min breathing motion with 8% linear strain). On top of this hardware, AlveoliX sells AXBiomodels (pre-developed monoculture, co-culture, immune, inflammation, and fibrosis models) and, since June 2023, AX Cells-on-Chip pre-seeded consumables. Its core technology is protected by a granted US patent on the breathing-motion lung-on-chip design and benefits from the regulatory tailwind of the FDA Modernization Act 2.0, which enables organ-on-chip data as standalone preclinical evidence.

The company operates a direct B2B sales model targeting pharmaceutical and biotech companies, contract research organizations, and academic research institutions, supported by participation in major scientific conferences (SOT, EUROTOX, ERS, EUROoCS) and a partnership-driven approach for technology validation and disease-specific applications. Named enterprise customers include Roche (Biochip Storming AX collaboration) and CSL Behring (sitem-insel hub partnership for lung disease translation), with academic collaborators including the Francis Crick Institute for iPSC-derived lung infection models and the University of Bern / Inselspital as founding academic partners. Revenue is generated through hardware sales of the chip ecosystem, consumables (chips, AX Cells-on-Chip), and professional services for custom biomodel development and research collaborations.

AlveoliX is headquartered in Bern, Switzerland (Freiburgstrasse 3, near sitem-insel) with a production site in Biel/Bienne at the Switzerland Innovation Park, and serves primarily European customers with selective North American outreach. Funding has come almost entirely from non-dilutive grants (Eurostars, Innosuisse, SNSF BRIDGE Discovery) rather than priced venture capital, and the company is led by co-CEOs Dr. Nina Hobi and Dr. Janick Stucki, with Prof. Olivier Guenat, the technology originator, remaining on the Board. In 2026, AlveoliX co-founded IAMPS, the first European industry association for microphysiological systems providers, alongside eight peer companies, positioning the firm as a standards-setter in the emerging organ-on-chip category.

AlveoliX AG firmographics

Firmographics
Name
AlveoliX AG
Legal name
AlveoliX AG
Website
https://alveolix.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
AlveoliX AG is a Swiss biotech tools company that develops proprietary organ-on-chip and lung-on-chip in vitro systems with breathing-motion simulation, selling hardware, consumables, and disease-specific biomodels to pharmaceutical, biotech, CRO, and academic customers for preclinical drug testing.
Ownership category
akta.pro rank

AlveoliX AG industry classification

Industry
Product category
Organ-on-Chip / Microphysiological Systems
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHLAGAIAG
Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers)

Keywords

  • Organ-on-chip technology
  • Lung-on-chip systems
  • In vitro preclinical models
  • Microphysiological systems
  • Barrier-on-chip platform

Where AlveoliX AG is headquartered

Location

Headquarters

HQ city
Bern
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

AlveoliX AG business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Organ-on-Chip Systems and Products: Sale of AX12 chips, AXLung-on-Chip System, AXBarrier-on-Chip System and related consumables for drug discovery and preclinical research.
  2. AXBiomodels and Custom Model Development: Provision of disease-specific biomodels and custom model development services for pharmaceutical and biotech company research needs.
  3. Research Collaborations: Collaborative research projects with academic institutions and pharmaceutical partners for specific disease applications.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

AlveoliX AG product offering

Product offering

Core offering

AlveoliX AG designs, manufactures, and sells proprietary organ-on-chip platforms — primarily the AXLung-on-Chip and AXBarrier-on-Chip Systems — that recreate human lung and barrier microenvironments in vitro with mechanical breathing simulation. The company supplies the AX12 chip, AXDock, AXExchanger, and AXBreather hardware, together with AXBiomodels (pre-developed toxicity, inflammation, and fibrosis models) and the AX Cells-on-Chip line of pre-seeded chips, for pharmaceutical and biotech drug discovery and preclinical testing applications.

Product overview

AlveoliX AG offers a modular organ-on-chip product ecosystem centered on two core platforms: the AXLung-on-Chip System and the AXBarrier-on-Chip System. The AXLung-on-Chip System includes the AX12 chip (96-well format with 6 independent units), AXDock, AXExchanger, and AXBreather components that work together to recreate breathing lung models with ultrathin membranes (3.5µm) and cyclic strain (12 cycles/min, 8% linear strain). The AXBarrier-on-Chip System provides barrier modeling capability. Both platforms use the AXBiomodels library (monoculture, co-culture, immuno, inflammation, fibrosis models) for specific testing applications. The AX Cells-on-Chip line extends the portfolio with pre-seeded cells for standardized workflows. The systems are designed for drug discovery, preclinical toxicity and efficacy testing, and are compatible with standard laboratory equipment and readouts including TEER, ELISA, rtPCR, and flow cytometry.

Differentiator

Problem solved

Functional benefit

Products and services

  • AXLung-on-Chip System A lung-on-chip system that replicates the human lung microenvironment with breathing motion, including the AX12 chip (ultrathin 3.5µm membrane with 3µm pores), AXDock connection hub, AXExchanger for fluid control, and AXBreather for pneumatic breathing simulation (12 cycles/min, 8% linear strain). Designed for pharmaceutical and biotech drug discovery and preclinical studies.
  • AXBarrier-on-Chip System A barrier-on-chip platform that recreates the air-blood barrier with human-derived cells for in vitro toxicity and efficacy testing in drug discovery and preclinical studies, supporting mono-culture, co-culture, and immune cell integration.
  • AX Cells-on-Chip Product line of cells pre-seeded on the AX chip platform, providing standardized, ready-to-use in vitro testing models for drug testing applications.
  • AXBiomodels Disease-specific in vitro biomodels including toxicity models (monoculture, co-culture, immuno), efficacy models (inflammation, fibrosis), and custom model development services for pharmaceutical and biotech company research needs.

Quantifiable outcome

  • 87% sensitivity in predicting drug-induced liver injury (FDA ISTAND pilot program for comparable MPS technologies)

Companies that use AlveoliX AG

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

AlveoliX AG technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

AlveoliX AG partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core, major and minor.

  • European WiFIX Consortium PartnerscoreStrategic or Co-development Partner · 9 June 2026European consortium awarded EUR 1 million Eurostars grant to develop Nexopore, a wireless electroporation-based system for delivering nucleic acid therapeutics. AlveoliX is part of this consortium focused on overcoming delivery challenges for nucleic acid therapeutics.
  • InSCREENeX GmbHcoreTechnology or IntegrationCo-developed new immortalized alveolar cell line (AXiAECs) combining InSCREENeX's CI-SCREEN methodology with AlveoliX's organ-on-chip technology. Cells derived from primary alveolar epithelial cells feature tight barrier formation and robust marker expression.
  • EpiEndo PharmaceuticalscoreStrategic or Co-development PartnerEPIColiX project under Eurostars program developing gut-on-chip model for drug testing. AlveoliX developing colon epithelium model for screening EpiEndo's lead compounds for ulcerative colitis treatment.
  • PANC-CKI ConsortiummajorStrategic or Co-development PartnerAlveoliX part of consortium led by CasInvent Pharma awarded €4M Eurostars grant for pancreatic cancer research. Consortium achieved top ranking in Czech Republic, Switzerland, and overall.
  • RochemajorStrategic or Co-development PartnerHosted first Biochip Storming AX event with Roche Basel to address challenges and opportunities of organ-on-chip technology within drug development pipeline.
  • CSL BehringcoreStrategic or Co-development PartnerCSL Behring, Insel Gruppe and AlveoliX joined forces within sitem-insel AG's hub to improve translation and find new treatments for lung diseases.
  • Francis Crick InstitutecoreStrategic or Co-development PartnerJoint development of first human lung-on-chip model using stem cells from a single donor, capable of simulating breathing motions and replicating lung disease for personalized medicine applications. Tested with tuberculosis infection.
  • University of Bern / ARTORG CentercoreStrategic or Co-development PartnerLong-term academic partnership for organ-on-chip technology development. Founding relationship where technology originated from Prof. Olivier Guenat's research group.
  • InselspitalcoreStrategic or Co-development PartnerSwitzerland's largest hospital group, partner in lung research and clinical translation of organ-on-chip technology for patient benefit.
  • IAMPS (Industry Alliance for Microphysiological Systems)coreStrategic or Co-development PartnerCo-founded with 8 other European MPS companies (BiomimX, Chiron, Dynamic42, InSphero, MIMETAS, NETRI, React4Life, TissUse) as the world's first industry association dedicated to representing microphysiological systems providers. Association aims to increase regulatory acceptance, create data-sharing platforms, and advance device standardization.
  • BRIDGE Discovery Project ConsortiummajorStrategic or Co-development PartnerSNSF/Innosuisse funded project with Université de Neuchâtel, CHUV, SIB, and SiMPLInext SA to establish novel solution for antibiotic resistance using environmental interference to fight lung fungal infections.
  • NA3RsC (North American 3Rs Collaborative)minorStrategic or Co-development PartnerPart of MPS initiative working to increase industry adoption and regulatory acceptance of MPS technologies with the goal of refining, reducing, and replacing research animals.

Scale indicators5 records

Recent moves6 records

Expansion highlights7 records

AlveoliX AG competitors and assessment

Company assessment

Direct peers

  • Emulate Inc. US-based organ-on-chip company commercializing the Emulate Liver-Chip and other organ models for pharma R&D. Direct competitor to AlveoliX's AXLung/AXBarrier-on-Chip platforms with overlapping target customers in big pharma and similar microfluidic chip-plus-instrument business model.
  • Dynamic42 GmbH: German organ-on-chip company developing immune-system and infection-on-chip models for pharma and academic research. Direct competitor, fellow IAMPS co-founder, and comparable European early-commercial MPS provider.
  • CN Bio Innovations: UK-based organ-on-chip company commercializing the PhysioMimix platform for liver and lung MPS models. Direct competitor with comparable single- and multi-organ chip offerings aimed at pharma toxicology and disease modeling.
  • NETRI: French organ-on-chip company industrializing microfluidic neural and organ-on-chip devices for pharma screening. Direct competitor in MPS hardware, fellow IAMPS co-founder, with overlapping target use cases in neurological and systemic drug testing.
  • BiomimX: Italian organ-on-chip startup focused on heart and vascular MPS models using beating-cardiac technology. Direct competitor and fellow IAMPS co-founder with similar early-stage European MPS positioning.
  • MIMETAS: Dutch organ-on-chip company offering the OrganoPlate platform for high-throughput 3D tissue models. Direct competitor targeting pharmaceutical drug discovery and toxicology with comparable organ-on-chip hardware, consumables, and custom model services.
  • React4Life: Italian organ-on-chip company commercializing the MIVO (Multi-In-Vitro-Organ) platform for fluid-dynamic tissue models. Direct competitor in MPS-based preclinical testing, fellow IAMPS co-founder, with comparable European pharma and academic customer base.
  • TissUse GmbH: German multi-organ-on-chip company offering the HUMIMIC chip systems for substance testing. Direct competitor in MPS hardware with overlapping pharma customer base and fellow IAMPS co-founder.
  • InSphero: Swiss 3D cell culture and organ-on-chip company providing liver, islet, and tumor microtissues for drug safety/efficacy testing. Direct competitor in MPS-based preclinical tools, fellow IAMPS co-founder, and similarly Swiss-based with overlapping pharma customers.

Regional players

  • Cherry Biotech: French organ-on-chip company offering the Chipster platform with temperature-controlled microfluidic MPS systems for academic and pharma research. Comparable European MPS provider serving overlapping applications in cell-based preclinical testing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

AlveoliX AG social profiles

Digital presence

AlveoliX AG financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AlveoliX AG leadership team

Management profile

Number of profiles

Profiles4 records

AlveoliX AG funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AlveoliX AG M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AlveoliX AG

What does AlveoliX AG do?

AlveoliX AG designs, manufactures, and sells proprietary organ-on-chip platforms — primarily the AXLung-on-Chip and AXBarrier-on-Chip Systems — that recreate human lung and barrier microenvironments in vitro with mechanical breathing simulation. The company supplies the AX12 chip, AXDock, AXExchanger, and AXBreather hardware, together with AXBiomodels (pre-developed toxicity, inflammation, and fibrosis models) and the AX Cells-on-Chip line of pre-seeded chips, for pharmaceutical and biotech drug discovery and preclinical testing applications.

Is AlveoliX AG a public or private company?

AlveoliX AG is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was AlveoliX AG founded?

AlveoliX AG was founded in 2019. It employs 11 to 50 people.

Where is AlveoliX AG based?

AlveoliX AG is headquartered in Bern, Switzerland, in the Europe region.

How does AlveoliX AG make money?

Three revenue lines are on record. Organ-on-Chip Systems and Products are the primary driver. The others are AXBiomodels and Custom Model Development and research Collaborations.

Who are AlveoliX AG's main competitors?

Direct peers on record are Emulate Inc., Dynamic42 GmbH, CN Bio Innovations, NETRI, BiomimX, MIMETAS, React4Life, TissUse GmbH and InSphero. Cherry Biotech is listed as a regional player.

Does AlveoliX AG have an API?

No public API is recorded for AlveoliX AG.

What industry is AlveoliX AG in?

AlveoliX AG's product category is Organ-on-Chip / Microphysiological Systems. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models), with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 334516 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals